Six-minute walk test in chronic respiratory disease: Easy to perform, not always easy to interpret by Neder, Jose Alberto
J Bras Pneumol. 2011;37(1):1-3
(6MWD); of the integrity of intrapulmonary 
gas exchange—based on oxygen-hemoglobin 
saturation; of cardiovascular stress—based on 
the heart rate; and of the stress associated with 
submaximal exercise—based on dyspnea and 
fatigue scores. Contrary to what the title of 
the review article suggests,(2) the 6MWT cannot 
be characterized as a test to assess respiratory 
dysfunction exclusively, because any physical 
activity involves the integrated functioning of 
multiple organ systems. However, the procedure 
has undoubtedly passed “the test of time”, and, 
as appropriately reviewed by the authors, there 
is clear evidence that the 6MWT is useful in 
different populations. 
Paradoxically, the interpretation of the 
6MWD (from an intraindividual or interindividual 
perspective), which is modulated by whether 
there is one or more previous test results for 
comparison, remains the most critical aspect 
of the 6MWT. In clinical practice, the most 
common challenge is to determine, in an 
adequate manner, the remaining functional 
capacity of patients without a previous 6MWT 
and in whom the 6MWD is not severely reduced 
(e.g., < 300-350 m in patients with COPD) or 
clearly normal (> 550-600 m). Because in this 
case patients cannot be their own “control” 
over time, two options remain: to compare 
the 6MWD to disease-specific severity intervals 
or to reference values. Currently, there are 
simply no disease-specific severity intervals for 
the most prevalent chronic lung diseases. The 
reference values also seem to be of little use, 
considering that, at best, predictive equations 
have coefficients of determination of 0.4 
(i.e., 60% of the variability of the 6MWD in 
healthy individuals remains uncertain).(3-5) More 
importantly, there is a wide variation in the 
lower limits of normality in distinct populations. 
In fact, a recent study sponsored by the Latin-
Chronic respiratory diseases are habitually 
accompanied by a (variable) reduction in the 
ability to perform activities of daily living with 
a degree of discomfort considered “acceptable” 
by individuals. In fact, it has long been held 
that standardized measurement of physical 
performance during a simple test involving an 
activity with which patients are familiar can 
provide clinically useful information regarding 
the ability of patients to face the increased 
physical demands that characterize daily life. 
In this context, it would be highly desirable 
to have a test with the following characteristics: 
a) involving the dislocation of the entire body 
mass (“dynamic exercise”) during an activity 
that is common to most individuals; b) being 
of sufficient duration for the physiological 
adjustments to the exercise to reach some degree 
of stability but not long enough to be limited 
by symptoms; and, last but not least, c) the 
intensity of the effort put forth being defined by 
the patients—although they are aware that their 
degree of exercise tolerance will be measured—
meaning that patients will pace themselves on 
the basis of how much farther they have to go. 
Such premises seem to be addressed by a walk 
test (premise a) that lasts six minutes (premise b) 
and is performed at a pace defined by patients, 
with standardized encouragement (premise 
c).(1) The applications of this test in different 
settings and clinical populations constitute the 
subject of an extensive and timely review article 
published in this issue of the Brazilian Journal of 
Pulmonology.(2) In that review, Morales-Blanhir 
et al. emphasize that, although the six-minute 
walk test (6MWT) provides limited information 
regarding the underlying mechanisms of exercise 
intolerance, the test can, when performed 
in accordance with a standard protocol,(1) 
provide the following indicators: of functional 
capacity—based on the six-minute walk distance 
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meters) will constitute a much greater fraction 
of the baseline value for the patient in range A 
than for that in range C (Figure 1). In addition, 
it remains unclear whether this relationship 
remains hyperbolic and with the same curvature 
when there is functional loss. Can we assume 
that a given absolute and relative reduction 
in the 6MWD essentially represents the same 
decrease in functional capacity that would have 
been expected had both values increased? Future 
studies should address those issues. At present, 
perhaps the best alternative is to recognize that 
the MID for the 6MWD probably depends on the 
baseline (or pre-intervention) 6MWD: shorter 
for patients with more severe disease and longer 
(albeit more difficult to achieve) for those with 
less severe disease (Figure 1). 
Review articles that are conceptually precise 
and adequately balanced by the best evidence 
available are always welcome. The article by 
Morales-Blanhir et al.(2) has those qualities and 
will certainly be useful for clinical pulmonologists 
American Thoracic Association(5) demonstrated 
that 6MWD values were higher in samples in 
Latin America (including a sample in the city of 
São Paulo, Brazil) than in those in countries in 
the northern hemisphere (Spain and the United 
States), a finding that might be related to the fact 
that Brazilian patients with COPD tend to walk 
more than do their counterparts (with the same 
degree of functional loss) in the United States. 
Therefore, except in extreme cases, there is still 
no definitive answer as to which 6MWD values 
clearly characterize and grade the functional 
incapacity of patients with chronic lung disease. 
Another alternative to maximize the information 
provided by the 6MWT involves the use of 
combined indices that take into consideration 
the metabolic cost of achieving a certain 6MWD 
(such as the 6MWD × body weight product) or, 
as recently suggested in a study conducted in 
Brazil, for patients with interstitial lung disease, 
the intensity of exercise-induced hypoxemia 
(such as the 6MWD/desaturation ratio).(6) 
The 6MWT can also be used over time to 
analyze, in an objective manner, the progression 
of functional loss or the potentially positive effect 
of therapeutic or rehabilitation interventions. 
The interpretation of variations in the 6MWD 
is even more complex, because the suggested 
values for the minimal important difference 
(MID)—“the smallest difference in score in the 
outcome of interest that informed patients or 
informed proxies perceive as important, either 
beneficial or harmful, and which would lead 
the patient or clinician to consider a change in 
the management”(7)—vary widely. In COPD, for 
instance, the MID for the 6MWD varies widely 
in terms of absolute values (from 25 m to 80 
m) and relative values (from 10% to 40%).(7-11) 
Methodological considerations aside, most of 
this variability might be due to the fact that the 
relationship between the 6MWD and functional 
capacity is not linear. In fact, as can be seen 
in Figure 1, the relationship is curvilinear 
(hyperbolic), the slope of the curve decreasing 
progressively as both variables increase. This 
means that a patient in range A of Figure 1 
(a patient who presents with a short 6MWD 
and low functional capacity) has greater room 
for improvement than does a patient in range 
C of Figure 1 (a patient who presents with a 
long 6MWD and near peak functional capacity). 
However, the same absolute improvement (in 
Figure 1 - Hyperbolic relationship between 
functional capacity (FC) and the six-minute walk 
distance (6MWD). Note the progressive reduction in 
the sensitivity of the 6MWD in reflecting positive 
variations in FC as a result of interventions (circle-
arrow interval on the x-axis). Therefore, a given 
improvement in FC will translate to a lower variation 
in the 6MWD if the pre-intervention 6MWD is longer 
(patient “C” vs. patient “A”). However, patient “A”, 
despite having greater theoretical potential for 
improvement in the 6MWD, commonly presents with 
worse baseline health status (i.e., lower biological 
potential for improvement). Another complicating 
factor is that improvement in FC is not linearly related 
to clinical outcomes that are relevant to the patient 
and attending physician. Therefore, the minimal 
important difference(7) for the 6MWD is expected to 
vary widely, as consistently demonstrated.(8-11) 
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and fellow physicians who specialize in different 
areas of medicine, as well as for paramedical 
professionals, who use the 6MWT to assess 
functional capacity. However, the definitive 
incorporation of the 6MWT into clinical practice 
seems to depend on the resolution of the 
complexities of the interpretation of specific 
values and their longitudinal variations in 
different populations of patients with chronic 
respiratory disease. 
José Alberto Neder  
Full Professor,  
Coordinator of the Setor de Função 
Pulmonar e Fisiologia Clínica do 
Exercício – SEFICE,  
Pulmonary Function and Exercise 
Physiology Section – and  
Head of the Department of Pulmonology, 
Universidade Federal de São Paulo/ 
Escola Paulista de Medicina – 
UNIFESP-EPM,  
Federal University of São Paulo/ 
Paulista School of Medicine –  
São Paulo, Brazil
